MetaCap

Quantum Cyber N.V. (QUCY) vs RenovoRx (RNXT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

RenovoRx (RNXT) has outperformed Quantum Cyber N.V. (QUCY) over the past year, gaining 18.3% versus a loss of 48.7%. Over five years, RNXT leads with a -85.3% price change compared with -94.8% for QUCY. RenovoRx is the larger company by market cap ($45.5 million vs $44.7 million), about 1.0 times the size.

RenovoRx converts more of its revenue into profit, with a net margin of -994.5% versus -3018.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

QUCY-48.75%RNXT+18.34%
+273%+94%-84%
Nov 21, 20251 yearNov 20, 2026
QUCY-94.78%RNXT-85.71%
+197%+43%-112%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

QUCY versus RNXT key metrics
MetricQUCYRNXT
Share price$0.512$0.942
Market cap$44.67M$45.45M
1-day change-7.25%-10.29%
YTD return-54.29%+12.14%
1-year return-48.75%+18.34%
5-year return-94.80%-85.26%
EPS (TTM)$-2.27$-0.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$537.08K$1.12M
Revenue growth (YoY)-39.92%+2511.63%
Net income (latest FY)$-16.21M$-11.17M
Gross margin72.58%70.88%
Operating margin-3004.97%-1113.98%
Net margin-3018.31%-994.48%
52-week high$4.93$2.59
52-week low$0.30$0.77
Distance from 52-week high-89.61%-63.63%
Analyst consensusnonenone
Avg. price target upside+1657.81%+656.90%
Average volume528.02K815.75K
Shares outstanding87.24M48.25M
Employees1017
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RNXT has outperformed QUCY by 67.1 percentage points over the past year.
  • RenovoRx is more profitable, keeping -994.5 cents of every revenue dollar as net income versus -3018.3 cents for Quantum Cyber N.V..
  • RenovoRx grew revenue faster in its latest fiscal year (+2511.63% vs -39.92%).

About Quantum Cyber N.V.

QUCY stock →

Quantum Cyber N.V. operates as a technology company focused on cybersecurity and quantum computing solutions.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

About RenovoRx

RNXT stock →

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

QUCY vs RNXT FAQ

Which is bigger, Quantum Cyber N.V. or RenovoRx?

RenovoRx (RNXT) is larger, with a market capitalization of $45.45M compared with $44.67M for Quantum Cyber N.V. (QUCY).

Which stock has performed better over the past year, QUCY or RNXT?

RNXT returned +18.34% over the past 12 months, compared with -48.75% for QUCY (price return, excluding dividends). Past performance does not predict future results.

Are Quantum Cyber N.V. and RenovoRx in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons